| |
|
|
|
|
|
|
|||
|
Blood, 15 August 2004, Vol. 104, No. 4, pp. 913.
Platelets feel your painHARVARD MEDICAL SCHOOL
Graham and colleagues have demonstrated that platelets express tachykinin receptors, respond to tachykinins such as substance P, and even secrete a substance Plike peptide.
The results of their studies hold a number of surprises. First, platelets aggregated and secreted granules in response to substance P. The authors demonstrated that tachykinin receptors NK1 (the preferred receptor for substance P) and NK3 (the preferred receptor for neurokinin B) are present in human platelets. Antibodies directed at NK1 impaired, but did not abrogate, platelet aggregation in response to substance P. Similarly, platelets from NK1 null mouse showed only a modestly impaired response to substance P. Thus, NK1 participates in substance Pinduced platelet activation, but other receptors likely contribute as well. Another surprise was that NK1 receptors are expressed in an activation-dependent manner. For example, stimulation with thrombin resulted in a 9-fold increase in NK1 receptor surface expression. In addition, the authors found that platelets released a substance Plike peptide upon activation. The fact that platelets express tachykinin receptors and release a substance Plike peptide upon activation raised the possibility that tachykinins could behave in an autocrine/paracrine manner. To test this possibility, the authors stimulated platelets with submaximal concentrations of thrombin in the presence of antibodies directed at the NK1 receptor. Under these conditions, anti-NK1 receptor antibody inhibited thrombin-induced aggregation. Platelets from NK1 receptordeficient mice also displayed a modest impairment of thrombin-induced aggregation induced by low thrombin concentrations. Taken together, these studies form strong evidence that tachykinins influence platelet function. Historically, platelets have served as an easily accessible cell model for neurons.5 The studies of Graham and colleagues reveal that platelets and neurons share a common set of stimulatory peptides and receptors. It is conceivable that under certain physiologic conditions tachykinins mediate cross talk between these 2 cell types. More plausibly, platelet tachykinins may participate as secondary agonists in hemostasis. The sharing of a common stimulatory axis has clinical implications. For example, do small molecule antagonists of tachykinin receptors, presently in clinical trials, represent bleeding risks? Might such therapeutics pose bleeding risks in combination with commonly used antiplatelet medications? These concerns await proof in a physiologic system that tachykinins function in hemostasis as they do in neurotransmission. References
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2004 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||